MAIA Biotechnology (MAIA) Total Current Liabilities (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Total Current Liabilities of $6.3 million for Q1 2026, up 25.01% year-over-year from $5.1 million in Q1 2025, and up 8.33% quarter-over-quarter from $5.8 million in Q4 2025.
MAIA Biotechnology (MAIA) Total Current Liabilities (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Total Current Liabilities for 6 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 25.01% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 25.01% YoY), while the FY2025 annual figure was $5.8 million, up 52.38% from the prior year.
- Total Current Liabilities rose to $6.3 million in Q1 2026 per MAIA's latest filing, from $5.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $10.0 million in Q3 2025 and bottomed at $2.5 million in Q3 2022.
- Historically, Total Current Liabilities has averaged $4.6 million across 5 years, with a median of $4.0 million in 2023.
- Annual changes were most pronounced in 2024 — Total Current Liabilities decreased 22.42% — and 2025, when it jumped 176.94%.
- MAIA Biotechnology's Total Current Liabilities stood at $3.3 million in 2022, then soared by 51.03% to $4.9 million in 2023, then retreated by 22.42% to $3.8 million in 2024, then soared by 52.38% to $5.8 million in 2025, then advanced by 8.33% to $6.3 million in 2026.
- Business Quant data shows MAIA's Total Current Liabilities at $6.3 million in Q1 2026, $5.8 million in Q4 2025, and $10.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | 6.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.26 Mn |
| Mar 31, 2026 | 6.32 Mn |
| Dec 31, 2025 | 5.84 Mn |
| Sep 30, 2025 | 9.99 Mn |
| Jun 30, 2025 | 5.04 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 3.51 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 4.94 Mn |
| Sep 30, 2023 | 4.15 Mn |
| Jun 30, 2023 | 3.27 Mn |
| Mar 31, 2023 | 3.77 Mn |
| Dec 31, 2022 | 3.27 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Dec 31, 2021 | 2.15 Mn |